Armata Pharmaceuticals, Inc.
AMEX:ARMP · New York Stock Exchange American
+$0.11 today
Vol 0.15M · Avg 0.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
79.5%
avg -56.1%
ROIC
-43.1%
avg -75.6%
ROA
-226.1%
avg -76.4%
Analysis
ROE is currently the strongest return metric at 79.5% versus its period average of -56.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Deborah L. Birx | Chief Executive Officer & Director | $851,908.00 | — | 69 | $212,458.00 | 0.58% |
Pierre Kyme | Chief Business Officer | $625,750.00 | — | 48 | $9,461.00 | 0.03% |
David House | Senior Vice President of Finance & Principal Financial Officer | $513,314.00 | — | 42 | $109,885.00 | 0.30% |
Bani Tchekanova | Head of Regulatory Strategy & Operations | — | — | — | — | — |
Peter Hubbard | Vice President of Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -10.6% | +37.5% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -10.6% over three years. Forward estimates point to Revenue at +37.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Nuvectis Pharma, Inc.
NASDAQ:NVCT
$284.09M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$62.14M
Who manages ARMP?
Armata Pharmaceuticals, Inc. (ARMP) lists 5 active executives. The top listed executive is Deborah L. Birx, Chief Executive Officer & Director.
Are ARMP insiders buying or selling?
Recent insider activity shows net buying of $162.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.